InvestorLens

REGN — REGENERON PHARMACEUTICALS

Health Care · Biotechnology

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying REGN?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 1 buying vs 0 selling last quarter
63
Macro Tailwind
Macro conditions are mixed for this sector
53
Congressional Activity
1 congressional purchase, 1 sale disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their REGN position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime). 1 congressional purchase, 1 sale disclosed in the last 6 months.

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Ray Dalio)
  • +4 tracked investors reported holding REGN at their latest filing
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About REGENERON PHARMACEUTICALS (REGN)

REGENERON PHARMACEUTICALS (REGN) appears in the most recent 13F filings of 4 tracked institutional investors. REGENERON PHARMACEUTICALS is classified in the Health Care sector (Biotechnology industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $614M. Across recent filings, tracked investors recorded 6 new positions, 6 increased, 13 reduced, and 5 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in REGN

40
/100
Mixed Activity
Added / Increased12
Reduced13
Exited5
BearishBullish
Crowded Trade Score™

How many top investors track REGN

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

REGN Ownership Composition

How REGENERON PHARMACEUTICALS is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
93% of tracked value
Institutions
4
tracked investors
Total Reported
$557M
combined 13F value
Types2
  • Multi-Strategy / Quant92.8%
  • Macro7.2%
Multi-Strategy / Quant(2)
92.8%
Macro(2)
7.2%

Tracked investors currently reporting REGN

4 tracked investors have since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    593.5K
    Value
    $370.1M
    % Portfolio
    0.04%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    235.6K
    Value
    $146.9M
    % Portfolio
    0.05%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    12.8K
    Value
    $8M
    % Portfolio
    0.01%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    51.3K
    Value
    $32M
    % Portfolio
    0.13%

Previously held REGN

These investors reported REGN in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Steve CohenPoint72 Asset Management150.6K$116.3MMar 31, 2026
Michael BurryScion Asset Management215K$112.9MJun 30, 2025
Andreas HalvorsenViking Global Investors97.7K$62MMar 31, 2025
Cathie WoodARK Investment Management12.6K$6.6MJun 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold REGN?
4 tracked institutional investors disclosed a position in REGN (REGENERON PHARMACEUTICALS) in their most recent 13F filing.
Who is the largest institutional holder of REGN?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in REGN, valued at $614M.
Did institutional ownership of REGN increase or decrease?
Across recent 13F filings, tracked investors recorded 6 new positions, 6 increased, 13 reduced, and 5 fully exited REGN.
What sector is REGN in?
REGENERON PHARMACEUTICALS is classified in the Health Care GICS sector, Biotechnology industry.
Where does this REGN ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.